TABLE 5.—LEUKEMIA REPORTED IN FOLLOW-UP SURVEY OF PATIENTS PREVIOUSLY REGISTERED FOR ADVERSE REACTION TO CHLORAMPHENICOL OR PHENYLBUTAZONE—SUMMARY OF CASES

| | Sex | Age, years | Leukemia | | Drug ingestion | | | | Initial reaction | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Type [1] | Latent period [2] | Drug [3] | Indication | Duration | Estimated dose, grams | Type | Latent period [4] |
| Case: | | | | | | | | | | |
| 1 | F | 67 | AML | 2½ years | C | Bladder and lung infection. | Intermittently—8 months | 14 | Pancytopenia (marrow-"aplastic anemia"). | 8 months. |
| 2 | M | 57 | CML | 3½ years | C | (?) | 5 days | 8 | Pancytopenia (marrow-"aregenerative anemia"). | 3 months. |
| 3 | F | 2 | ALL | 5 months | C | Septicemia | 3 days | 5 | Leukopenia (rem tted after androgen therapy). | 3 weeks. |
| 4 [5] | M | 14 | ASCL | 1 month | C | Tonsilitis | 10 days | 10 | Leukopenia thrombocytopenia | 1 week. |
| 5 [5] | F | 17 | ASCL | 2 months | C | do | 10 days | 10 | Leukopenia, thrombocytopenia | 1 week. |
| 6 [5] | F | 71 | MF+MM | Several years | P | Arthritis | Intermittently—several years | [6] 0.4–0.6 | Pancytopenia (marrow-"fibrosis"). | Several years. |

[1] CML=chronic myelogenous leukemia, AML=acute myelogenous leukemia, ALL=acute lymphocytic leukemia, ASCL=acute stem-cell leukemia, and MF+MM=myelofibrosis and myeloid metaplasia.
[2] Latent period=interval between start of drug therapy and diagnosis of leukemia.
[3] C=chloramphenicol, P=phenylbutazone.
[4] Latent period=interval between start of drug therapy and diagnosis of initial blood dyscrasia.
[5] Leukemia in cases 4 through 6 was mentioned on original report of adverse reaction to the registry and was excluded from survey for any calculation of leukemia frequencies.
[6] Daily.